Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [3] - The company's lead program, Zumilokibart (APG777), is being developed primarily for AD, which is identified as the largest and least penetrated market within I&I [3] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which target established mechanisms of action and utilize advanced antibody engineering [3] Upcoming Events - Management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 a.m. E.T. [1] - The company will also attend the UBS Biotech Summit Miami on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026 [1] Investor Relations - For investor inquiries, Noel Kurdi serves as the VP of Investor Relations at Apogee Therapeutics [4] - Media inquiries can be directed to Dan Budwick at 1AB [4]

Summary of Apogee Therapeutics Conference Call Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Industry**: Biotechnology, specifically focused on treatments for atopic dermatitis and asthma - **Key Product**: Zumilokibart, targeting type two inflammation Core Insights and Arguments 1. **Company Vision and Progress**: Apogee was founded to provide better treatment options for patients with atopic dermatitis and related conditions. The company is transitioning from a dosing schedule of every 2-4 weeks to potentially every 3-6 months without sacrificing efficacy, aiming to prove this in upcoming studies [2][3][10]. 2. **Phase 1b Asthma Data**: The company reported a 60% reduction in FeNO (Fractional Exhaled Nitric Oxide) from baseline in a study of 19 mild to moderate asthma patients, indicating competitive efficacy compared to other approved agents [5][6]. 3. **Market Opportunity**: There is a 30% overlap between atopic dermatitis and asthma patients, which allows Apogee to expand its market reach into allergist and pulmonologist offices, potentially increasing revenue [7][8]. 4. **Efficacy and Safety**: Apogee aims to demonstrate rapid itch relief and lesional benefits comparable to existing treatments like Dupixent. The company is also focused on maintaining a favorable safety profile, particularly concerning conjunctivitis rates, which are common in this treatment class [10][18][19]. 5. **Phase 3 Studies**: The company is preparing to initiate Phase 3 studies to confirm dosing and efficacy, with expectations of replicating positive results from earlier trials [13][35]. Additional Important Points 1. **Dosing Flexibility**: Apogee's formulation allows for flexible dosing without compromising efficacy, which could lead to better patient adherence and outcomes [36][39]. 2. **Financial Position**: The company has over $900 million in cash, providing a runway into the second half of 2028, which supports ongoing clinical trials and potential product launch [70][71]. 3. **Launch Timeline**: Apogee plans to launch Zumilokibart in 2029, positioning itself as a first-line treatment in the atopic dermatitis market, directly competing with Dupixent [66][67]. 4. **Combination Therapies**: The company is exploring combination therapies with its lead product, Zumilokibart, and other agents, aiming to enhance treatment efficacy for patients who may not respond adequately to monotherapy [54][57]. Conclusion Apogee Therapeutics is positioned to make significant advancements in the treatment of atopic dermatitis and asthma with its innovative product, Zumilokibart. The company is focused on proving its efficacy and safety through ongoing clinical trials while preparing for a strategic market entry in 2029.

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [2] - The company's lead program, Zumilokibart (APG777), is primarily aimed at treating AD, which is identified as the largest and least penetrated market within I&I [2] - Apogee's antibody programs are designed to enhance efficacy and dosing by targeting established mechanisms of action and utilizing advanced antibody engineering to improve properties such as half-life [2] Upcoming Events - Management of Apogee Therapeutics will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. E.T. [1] - A live and archived webcast of the event will be accessible on the company's website under the Investors section [1]

Core Insights - Apogee Therapeutics is focused on advancing treatments in immunology, specifically optimizing the IL-13 pathway for inflammatory diseases [1] - The company has a strong financial position with a cash reserve of $913 million, expected to support operations until 2028 [1][5] - Citigroup maintains a "Buy" rating for Apogee Therapeutics despite a recent stock price decline, indicating strong confidence in the company's future [2][5] Financial Performance - Apogee's market capitalization is approximately $3.84 billion, with a trading volume of 3,080,567 shares [4] - The stock price has fluctuated between $68.02 and $78.78 during the trading day, with a recent price of $70.02 after a 12.32% decrease [2][4] Product Development - Apogee's drug, Zumilokibart, is a promising candidate with an extended half-life and a clean safety profile, positioning it as a strong competitor against Dupixent [3][5] - Physician surveys indicate a preference for treatments with reduced dosing frequency, aligning with Apogee's product strategy [3]

Core Insights - Apogee Therapeutics (APGE) is positioned at a significant juncture that presents a reasonable, yet risk-weighted opportunity for investors interested in next-generation biologic products [1] Company Analysis - The company is characterized by a strong inclination towards high-growth sectors that are expected to experience exponential expansion [1] - Apogee Therapeutics focuses on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Approach - The investment strategy involves a combination of fundamental analysis and future trend prediction, emphasizing the potential for substantial returns through innovation [1]

Core Insights - The conference call is hosted by Apogee Therapeutics, focusing on the company's latest developments and clinical programs [1][2] - The lead program discussed is zumilokibart (APG777), aimed at addressing asthma treatment [3] Company Developments - CEO Michael Henderson will introduce Apogee's latest developments and the goal of delivering a robust pipeline [3] - The call will include a presentation of Phase Ib interim results for zumilokibart in patients with mild to moderate asthma by Chief Medical Officer Carl Dambkowski [3]

Apogee Therapeutics Conference Call Summary Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Lead Program**: Zumilocobart (APG-777), targeting asthma and atopic dermatitis Key Industry Insights - **Market Potential**: The asthma biologics market is projected to exceed $15 billion, with a growing demand for long-acting treatments - **Competitive Landscape**: Dupixent is currently the market leader, approved for both asthma and atopic dermatitis, but requires dosing every two weeks Core Developments - **Phase 1B Results**: - Zumilocobart demonstrated a 60% reduction in FeNO (fractional exhaled nitric oxide) after a single 720 mg dose, indicating robust efficacy comparable to Dupixent [11][12] - Sustained FeNO suppression was observed for at least 16 weeks, with some patients showing effects lasting up to 32 weeks [12][16] - The trial enrolled 19 adult patients with mild to moderate asthma, specifically targeting those with type 2 inflammation [13][18] Future Plans - **Upcoming Data Releases**: - 52-week maintenance data from the APEX phase 2 study in atopic dermatitis expected in Q1 2026 - Dose optimization study results in Q2 2026 - Initiation of phase 3 studies for Zumilocobart planned for this year [5][27] Pipeline Expansion - **Combination Therapies**: - APG-279, a fixed-dose combination of IL-13 and OX40 ligand inhibition, is currently enrolling patients in a head-to-head study against Dupixent [6][7] - APG-273, a combination of IL-13 and TSLP inhibition, is also under exploration [7] Safety and Efficacy - **Safety Profile**: - Zumilocobart was well tolerated with no serious adverse events reported; the only notable side effect was gastroesophageal reflux disease in two patients [15] - The safety profile aligns with expectations for IL-13 targeting therapies [15][72] Market Strategy - **Commercial Positioning**: - Apogee aims to differentiate Zumilocobart by offering a long-acting biologic with dosing every three to six months, potentially transforming patient care [26][27] - The dual indication for asthma and atopic dermatitis is expected to enhance market access and pricing leverage [35] Scientific Validation - **Mechanism of Action**: - IL-13 is identified as a key driver in asthma pathology, influencing mucus production and airway inflammation [20][24] - Previous trials with other IL-13 inhibitors showed suboptimal results due to underdosing and broad patient selection; Zumilocobart's design addresses these issues [12][13] Conclusion - **Transformational Year Ahead**: - Apogee anticipates a pivotal year with multiple data readouts and the potential to establish Zumilocobart as a best-in-class therapy for asthma and atopic dermatitis [28][29]

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...

Core Insights - Apogee Therapeutics announced positive interim results from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma, demonstrating rapid and durable suppression of FeNO, a key biomarker of Type 2 inflammation [3][5][6] - The company aims to advance zumilokibart in asthma and atopic dermatitis, with significant milestones expected in 2026, including the initiation of Phase 3 trials [4][8] Phase 1b Trial Results - The Phase 1b trial involved 19 adult patients with mild-to-moderate asthma, showing a maximum absolute mean FeNO reduction of 45 ppb, representing a 60% decrease from baseline after a single dose of 720 mg of zumilokibart [5][6] - The treatment exhibited a favorable safety profile, with no serious adverse events reported and only two patients experiencing gastroesophageal reflux disease [6][7] Future Development Plans - Zumilokibart is advancing in Phase 2 APEX trials for atopic dermatitis, with Part A maintenance data readout expected in Q1 2026 and Part B induction data readout on track for Q2 2026 [8][10] - The company has a strong cash position of $913 million, providing a runway into the second half of 2028, supporting the potential launch of zumilokibart in 2029 [8][10] Market Potential - Apogee aims to establish a best-in-class profile for zumilokibart in the atopic dermatitis market, projected to exceed $50 billion, while also expanding its indications for other inflammatory and immunology diseases [8][10] - The company is focused on serial innovation in atopic dermatitis and plans to report multiple clinical data readouts in 2026, setting the stage for potential Phase 3 trial initiation [4][8]

Core Insights - Apogee is preparing for a transformative year in 2026 with significant clinical readouts planned, including data points for their LEAP program and asthma studies [5] Group 1: Clinical Developments - In Q1 2026, Apogee will present data for their LEAP program (777) in atopic dermatitis (AD) and maintenance data, along with asthma data for the same compound [5] - Q2 2026 will feature Part B of Phase II trials, focusing on the dose response curve for 777 in AD [5] - The second half of 2026 will see a combination trial of IL-13 and OX40 ligand, with a Phase Ib trial ongoing against DUPI [5]